GT Biopharma, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
GTBP$4.42-2.6%Stored close · as of Nov 6, 2026
Contents
Item 1. Financial Statements
| Condensed Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 | 3 | |
| Condensed Statements of Operations for the three and nine months ended September 30, 2025 and 2024 (Unaudited) | 4 | |
| Condensed Statements of Stockholders’ Equity (Deficit) and Mezzanine Equity for the three and nine months ended September 30, 2025 and 2024 (Unaudited) | 5 | |
| Condensed Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 (Unaudited) | 7 | |
| Notes to Unaudited Condensed Financial Statements | 8 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 22 |
|---|---|---|
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 30 |
| Item 4. | Controls and Procedures | 30 |
| PART II OTHER INFORMATION | ||
| Item 1. | Legal Proceedings | 31 |
| Item 1A. | Risk Factors | 32 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 32 |
| Item 3. | Defaults Upon Senior Securities | 32 |
| Item 4. | Mine Safety Disclosures | 32 |
| Item 5. | Other Information | 32 |
| Item 6. | Exhibits | 33 |
| SIGNATURES | 35 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.